To clarify the specific mechanism of tyrosine metabolizing enzymes regulating the malignant phenotype of glioma, we first calculated the optimal “cutpoint” using the R package algorithm and divided glioma patients into two groups according to the expression levels of HPD, HGD, and FAH (Supporting Information: Figure 2A,B). The gene discussed is HPD; the disease is central nervous system cancer.